U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07652515) titled 'A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer' on June 11.
Brief Summary: This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).
Study Start Date: Aug. 17
Study Type: INTERVENTIONAL
Condition:
Neoplasms, Endometrial
Intervention:
DRUG: Dostarlimab
Dostarlimab will be administered.
DRUG: Carboplatin
Carboplatin will be administered.
DRUG: Paclitaxel
Paclitaxel will be administered....